Product Name :
EC330
Description:
EC330 is a leukemia inhibitory factor (LIF) inhibitor.
CAS:
2016795-77-8
Molecular Weight:
462.57
Formula:
C30H32F2O2
Chemical Name:
(1S,3aS,3bS,10R,11aS)-10-(4-cyclopropylphenyl)-1-(1,1-difluoroprop-2-yn-1-yl)-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
Smiles :
C[C@]12C[C@@H](C3[C@@H](CCC4=CC(=O)CCC4=3)[C@@H]1CC[C@@]2(O)C(F)(F)C#C)C1C=CC(=CC=1)C1CC1
InChiKey:
OWPPSPZDYGHPAN-GCNJZUOMSA-N
InChi :
InChI=1S/C30H32F2O2/c1-3-30(31,32)29(34)15-14-26-24-12-10-21-16-22(33)11-13-23(21)27(24)25(17-28(26,29)2)20-8-6-19(7-9-20)18-4-5-18/h1,6-9,16,18,24-26,34H,4-5,10-15,17H2,2H3/t24-,25+,26-,28-,29-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
EC330 is a leukemia inhibitory factor (LIF) inhibitor.|Product information|CAS Number: 2016795-77-8|Molecular Weight: 462.{{Tazemetostat} site|{Tazemetostat} Apoptosis|{Tazemetostat} Purity & Documentation|{Tazemetostat} In stock|{Tazemetostat} custom synthesis|{Tazemetostat} Epigenetic Reader Domain} 57|Formula: C30H32F2O2|Chemical Name: (1S,3aS,3bS,10R,11aS)-10-(4-cyclopropylphenyl)-1-(1,1-difluoroprop-2-yn-1-yl)-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one|Smiles: C[C@]12C[C@@H](C3[C@@H](CCC4=CC(=O)CCC4=3)[C@@H]1CC[C@@]2(O)C(F)(F)C#C)C1C=CC(=CC=1)C1CC1|InChiKey: OWPPSPZDYGHPAN-GCNJZUOMSA-N|InChi: InChI=1S/C30H32F2O2/c1-3-30(31,32)29(34)15-14-26-24-12-10-21-16-22(33)11-13-23(21)27(24)25(17-28(26,29)2)20-8-6-19(7-9-20)18-4-5-18/h1,6-9,16,18,24-26,34H,4-5,10-15,17H2,2H3/t24-,25+,26-,28-,29-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 20 mg/mL (43.{{Tyloxapol} MedChemExpress|{Tyloxapol} {Biochemical Assay Reagents}|{Tyloxapol} Activator|{Tyloxapol} Protocol|{Tyloxapol} Description|{Tyloxapol} supplier} 24 mM; Need ultrasonic).PMID:33300444 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|EC330 shows marked specificity in MCF-7 cells overexpressing LIF verses MCF-7 cells. EC330 further shows cytoskeletal disruption and targeting cancer-associated fibroblasts (CAFs) through inhibition of alpha-SMA but not beta-tubulin.|In Vivo:|EC330 treatment (0.1, 0.5 and 2.5 mg/kg) dose dependently reduces tumor burden in ovarian (IGROV-1) and triple negative breast cancer (MDA-MB-231) cell xenografted mouse models as well as MDA-MB-231 PDX models. EC330 exhibits no reactivity towards thiol-cysteine residues, no off target binding to major receptors, kinases or ion channels. EC330 is orally bioavailable and found to be safe and tolerable in toxicity studies.|Products are for research use only. Not for human use.|
